Faculty of Biology, Medicine and Health

The University of Manchester

  (MRC DTP) Investigating the protective properties of angiotensin-converting enzyme inhibitors after haemorrhagic stroke

  , ,  Friday, November 15, 2024  Competition Funded PhD Project (Students Worldwide)

About the Project

Intracerebral haemorrhage (ICH) is a catastrophic form of stroke caused by spontaneous bleeding in the brain and is a leading global cause of adult disability. There is an urgent requirement to identify widely accessible and effective acute medical treatments to reduce brain injury caused by ICH (Withers et al, 2020). Angiotensin converting enzyme inhibitors (ACE-I) are a widely used class of renin-angiotensin aldosterone system inhibitors that act as blood pressure lowering medications to prevent and/or treat cardiovascular diseases, including stroke. Although primarily used to manage hypertension, increasing evidence indicates that ACE-I may offer cellular protection via an antioxidant function (Wzgarda et al, 2017). Using an unbiased zebrafish drug screening approach, we have shown that the ACE-Is, ramipril and quinapril, significantly reduce brain cell death acutely after spontaneous brain haemorrhage (Crilly et al, 2018; Crilly et al, 2022). Furthermore, our recent unpublished work shows that acute ACE-I treatment is associated with a significant reduction in brain cell death in a mouse model of ICH. We have also shown that ACE-Is may be promising clinically. We found treatment with an ACE-I after ICH to be independently associated with better 90-day recovery in 2611 participants in the INTERACT2 clinical trial (Anderson et al, 2013; Crilly et al, 2022). Preliminary data obtained from the zebrafish ICH model indicates that acute ACE-I treatment is associated with reduced mitochondrial protein expression and decreased mitochondrial stress. Given mitochondrial dysfunction is a significant contributor to brain injury, we hypothesise that ACE-I treatment offers neuroprotection after ICH by reducing mitochondrial stress. To study this hypothesis, we will utilise a combination of zebrafish and in vitro models of ICH with live imaging, flow cytometry, transcriptomics and molecular biology to determine the mechanisms associated with ACE-I treatment and neuroprotection after ICH. This study will provide translational insight to support a role for ACE-Is in post-ICH treatment and will provide essential mechanistic information for future clinical studies. 

 https://www.braininflamelab.org/ 

https://research.manchester.ac.uk/en/persons/paul.kasher 

https://research.manchester.ac.uk/en/persons/adrian.parry-jones 

https://research.manchester.ac.uk/en/persons/stuart.allan 

Eligibility 

Applicants must have obtained or be about to obtain a minimum Upper Second class UK honours degree, or the equivalent qualifications gained outside the UK, in a relevant discipline.  

Before you Apply 

Applicants must make direct contact with preferred supervisors before applying. It is your responsibility to make arrangements to meet with potential supervisors, prior to submitting a formal online application.  

How to Apply 

To be considered for this project you MUST submit a formal online application form – on the application form you must select MRC DTP PhD Programme. If you select the incorrect programme your application cannot be considered. Full details on how to apply can be found on the MRC DTP website  

Your application form must be accompanied by a number of supporting documents by the advertised deadlines. Without all the required documents submitted at the time of application, your application will not be processed and we cannot accept responsibility for late or missed deadlines. Incomplete applications will not be considered.  If you have any queries regarding making an application please contact our   

Equality, Diversity and Inclusion  

Equality, diversity and inclusion is fundamental to the success of The University of Manchester, and is at the heart of all of our activities. The full Equality, diversity and inclusion statement can be found on the website  

Biological Sciences (4) Medicine (26)

Funding Notes

Studentship funding is for 4 years and covers tuition fees and an annual stipend. This does not include any costs associated with relocation. 


References

Anderson CS, Heeley E, Huang Y, Wang J, Stapf C, Delcourt C, Lindley R, Robinson T, Lavados P, Neal B, Hata J, Arima H, Parsons M, Li Y, Wang J, Heritier S, Li Q, Woodward M, Simes RJ, Davis SM, Chalmers J; INTERACT2 Investigators. Rapid blood-pressure lowering in patients with acute intracerebral hemorrhage. N Engl J Med. 2013 Jun 20;368(25):2355-65. doi: 10.1056/NEJMoa1214609.

Crilly S, Njegic A, Laurie SE, Fotiou E, Hudson G, Barrington J, Webb K, Young HL, Badrock AP, Hurlstone A, Rivers-Auty J, Parry-Jones AR, Allan SM, Kasher PR. Using zebrafish larval models to study brain injury, locomotor and neuroinflammatory outcomes following intracerebral haemorrhage. F1000Res. 2018 Oct 8;7:1617. doi: 10.12688/f1000research.16473.2.

Crilly S, Parry-Jones A, Wang X, Selley JN, Cook J, Tapia VS, Anderson CS, Allan SM, Kasher PR. Zebrafish drug screening identifies candidate therapies for neuroprotection after spontaneous intracerebral haemorrhage. Dis Model Mech. 2022 Mar 1;15(3):dmm049227. doi: 10.1242/dmm.049227.

Withers SE, Parry-Jones AR, Allan SM, Kasher PR. A Multi-Model Pipeline for Translational Intracerebral Haemorrhage Research. Transl Stroke Res. 2020 Dec;11(6):1229-1242. doi: 10.1007/s12975-020-00830-z.

Wzgarda A, Kleszcz R, Prokop M, Regulska K, Regulski M, Paluszczak J, Stanisz BJ. Unknown face of known drugs - what else can we expect from angiotensin converting enzyme inhibitors? Eur J Pharmacol. 2017 Feb 15;797:9-19. doi: 10.1016/j.ejphar.2016.12.031.

Open Days


Register your interest for this project



Where will I study?

Faculty of Biology, Medicine and Health

Tackle real world challenges, make a difference, and elevate your career with postgraduate research in the Faculty of Biology, Medicine and Health at Manchester. From biochemistry to neuroscience, cancer sciences to medicine, audiology to mental health and everything in between, we offer a wide range of postgraduate research projects, programmes and funding which will allow you to immerse yourself in an area of research you’re passionate about.

Why study at Faculty of Biology, Medicine and Health?

Ranked the best place to live in the UK (The Economist Global Liveability Index, 2022), Manchester boasts world-class culture, iconic sports, a thriving music and food scene, and much more. It's not just a place to research, it's a place to call home.

Experience PhD life as part of a diverse postgraduate research community of more than 1,000 postgraduate researchers at the 29th most international university in the world (Times Higher Education, 2023).

With 93% of research activity at the University rated as 'world-leading' or 'internationally excellent' (Research Excellence Framework, 2021), you'll get the chance to have an impact on global health and science challenges.

1000+

postgraduate students

220

PhDs

6

ranked in UK - QS (2025)

Manchester  United Kingdom

main campus

Upcoming Open Days & Webinars


About Faculty of Biology, Medicine and Health

At Manchester, postgraduate researchers are at the heart of our mission to tackle pressing global challenges in biological, medical and healthcare sciences - and you could be too.

By choosing Manchester for your postgraduate research, you’ll be joining a university with an exceptional research reputation, where 93% of research is world-leading or internationally excellent (REF, 2021) and where your work will have real-world impact.

You’ll research in world-class facilities alongside leading experts at the forefront of innovation, collaborating across disciplines to pioneer new treatments, advance scientific knowledge, and improve healthcare globally.

Supported by our dedicated Doctoral Academy and strong industry links, you'll experience PhD life in a vibrant, welcoming and diverse postgraduate research community.

And you’ll leave with the specialist knowledge, research experience and transferable skills that will shape your future in academia, research or industry.





Main campus

The University of Manchester

Manchester

North West

United Kingdom

PhD saved sucessfully

(International Partnership Studentship) Using white matter network alterations relating to stroke risk to predict cognitive and health outcomes

The project aims to investigate how age-related changes in brain white matter impact upon cognitive and health outcomes. Using advanced software and MRI data from the UK Biobank, the researchers will create effective cross-sectional and longitudinal models of how white matter abnormalities predict cognitive function. Read more
More details

(MB-PhD) Gene regulatory networks driving metastatic progression in oesophageal adenocarcinoma

Oesophageal adenocarcinoma (OAC) incidence is increasing and yet survival rates remain very poor. There are limited treatment options, especially for metastatic disease, which is especially problematic as patients usually present with late stage disease. Read more
More details

(MB-PhD) MYST Histone Acetyltransferases as Therapeutic Targets in Acute Myeloid Leukaemia

Cytotoxic chemotherapy has been the standard of care for treatment of acute myeloid leukaemia (AML) for the last 50 years. Unfortunately, more often than not, it fails to cure patients, and the 5 years survival rate for all-comers with AML is only around 20%. Read more
More details

(MB-PhD)Immunomodulation in multiple myeloma

Multiple myeloma is a devastating B-cell malignancy for which there is no cure. The development of immunomodulatory drugs (IMiDs) has proved transformative to multiple myeloma care, however, their remain unanswered questions related to the mechanism of action of this important drug class. Read more
More details

(MRC DTP CASE) Developing a cortical organoid model of genetic autism to understand early brain development

Neurodevelopmental conditions including autism and ADHD affect 4-8% of the paediatric population. These conditions present in the preschool period, are highly heritable and can severely affect quality of life, academic and occupational functioning. Read more
More details

(MRC DTP CASE) Drug Binding on human G-Protein Coupled Receptors under Tension-Altered Biomechanics in Diseases

Integral membrane proteins (MPs) constitute a significant part of the genome and are targets of ~30% of therapeutics. However, structural and functional understanding of these proteins often lags behind that of their soluble counterparts. Read more
More details

(MRC DTP) Circadian mechanisms in psoriasis: translating genomic and computational analysis to clinical care.

Despite numerous lines of evidence supporting a role for the circadian clock regulating multiple immunological axes, the dominant cell type driving rhythmic disease expression in psoriasis remains undetermined and there has been no progress on time-of-day regulation of psoriasis. Read more
More details

(MRC DTP) Combinatorial targeting of multiple disease mechanisms in drug-resistant epilepsy using microRNA inhibitors

Epilepsy is one of the most common chronic neurological diseases, affecting ~70 million people worldwide. Epilepsy is characterised by susceptibility to spontaneous seizures, and can also include challenges with cognition, sleep and mental health. Read more
More details

(MRC DTP) Controlling G-protein coupled receptors to understand and treat obesity

The socioeconomic burden of obesity is ever increasing. Therefore, deciphering the neural substrates that control energy intake, expenditure and partitioning is an important step to developing novel treatments to reduce obesity rates. Read more
More details